Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
Colorcon
Chubb
Argus Health
Teva
Queensland Health
McKesson
Covington
US Department of Justice

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,462,058

« Back to Dashboard

Which drugs does patent 6,462,058 protect, and when does it expire?

Patent 6,462,058 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs.

Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in twenty-five countries.
Summary for Patent: 6,462,058
Title: Benzimidazole compound crystal
Abstract:A novel crystal of (R)-2-[[[3-methyl-4-(2, 2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
Inventor(s): Fujishima; Akira (Sanda, JP), Aoki; Isao (Kawanishi, JP), Kamiyama; Keiji (Ibaraki, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:09/674,624
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,462,058

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-001 Jan 30, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,462,058

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11-171509Jun 17, 1999

Non-Orange Book US Patents Family Members for Patent 6,462,058

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,664,276 Benzimidazole compound crystal ➤ Subscribe
8,552,198 Benzimidazole compound crystal ➤ Subscribe
7,737,282 Benzimidazole compound crystal ➤ Subscribe
9,145,389 Benzimidazole compound crystal ➤ Subscribe
8,030,333 Benzimidazole compound crystal ➤ Subscribe
6,939,971 Benzimidazole compound crystal ➤ Subscribe
7,339,064 Benzimidazole compound crystal ➤ Subscribe
7,569,697 Benzimidazole compound crystal ➤ Subscribe
8,884,019 Benzimidazole compound crystal ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,462,058

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 031069 ➤ Subscribe
Argentina 079473 ➤ Subscribe
Argentina 093609 ➤ Subscribe
Argentina 100473 ➤ Subscribe
Argentina 103295 ➤ Subscribe
Austria 391126 ➤ Subscribe
Australia 5247800 ➤ Subscribe
Australia 778820 ➤ Subscribe
Brazil 0011674 ➤ Subscribe
Brazil PI0011674 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Colorcon
Cerilliant
Chinese Patent Office
Teva
Queensland Health
Boehringer Ingelheim
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot